Literature DB >> 25474182

Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis.

Don B Sanders1, Zhanhai Li, Alan S Brody.   

Abstract

RATIONALE: Abnormalities on chest computed tomography (CT) in children with cystic fibrosis (CF) have been shown to correlate with short-term measures of lung disease. Chest CT scores offer promise as a potential surrogate end point in CF; however, there is limited information available on the ability of chest CT scores to predict future morbidity.
OBJECTIVES: Determine whether chest CT scores are associated with the rate of pulmonary exacerbations over the next 10 years.
METHODS: Ten years of follow-up data were obtained from the CF Foundation Patient Registry for 60 children enrolled in the Pulmozyme Early Intervention Trial and who had chest CT scans at baseline.
MEASUREMENTS AND MAIN RESULTS: Multivariable Poisson regression was used to compare Brody CT scores and the number of pulmonary exacerbations in the following 10 years. At the time of the chest CT, the mean (SD) age was 10.6 (1.7) years. A 1-point increase in the Brody CT score was associated with an increase in the mean (95% confidence interval) rate of pulmonary exacerbations of 1.39 (1.15, 1.67) (P < 0.001). Brody CT scores were more strongly associated with the number of pulmonary exacerbations than FEV1 % predicted at the time of the chest CT (P = 0.037 by chi-square test).
CONCLUSIONS: There is a significant association between Brody CT scores and the rate of pulmonary exacerbations up to 10 years later. This association is stronger than for FEV1 obtained at the time of the CT, suggesting that chest CT scores offer improved ability to predict future outcomes.

Entities:  

Keywords:  Brody scores; FEV1; bronchiectasis; epidemiology

Mesh:

Year:  2015        PMID: 25474182      PMCID: PMC5466157          DOI: 10.1513/AnnalsATS.201407-338OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  36 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation.

Authors:  Martine Loeve; Wim C J Hop; Marleen de Bruijne; Peter T W van Hal; Phil Robinson; Moira L Aitken; Jonathan D Dodd; Harm A W M Tiddens
Journal:  Am J Respir Crit Care Med       Date:  2012-03-08       Impact factor: 21.405

3.  Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF.

Authors:  C M Owens; P Aurora; S Stanojevic; A Bush; A Wade; C Oliver; A Calder; J Price; S B Carr; A Shankar; Janet Stocks
Journal:  Thorax       Date:  2011-03-21       Impact factor: 9.139

4.  Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.

Authors:  Mark O Wielpütz; Michael Puderbach; Annette Kopp-Schneider; Mirjam Stahl; Eva Fritzsching; Olaf Sommerburg; Sebastian Ley; Migle Sumkauskaite; Jürgen Biederer; Hans-Ulrich Kauczor; Monika Eichinger; Marcus A Mall
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

5.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Authors:  Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

6.  Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.

Authors:  Becky A Briesacher; Alexandra L Quittner; Hassan Fouayzi; Jie Zhang; Andrine Swensen
Journal:  Pediatr Pulmonol       Date:  2011-04-04

7.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

Authors:  M Corey; L Edwards; H Levison; M Knowles
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

8.  Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis.

Authors:  Alan S Brody; Heidi Sucharew; Jonathan D Campbell; Steven P Millard; Paul L Molina; Jeffrey S Klein; Joanne Quan
Journal:  Am J Respir Crit Care Med       Date:  2005-08-11       Impact factor: 21.405

9.  Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis.

Authors:  P A de Jong; Y Nakano; M H Lequin; J R Mayo; R Woods; P D Paré; H A W M Tiddens
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

10.  High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests.

Authors:  Alan S Brody; Jeffrey S Klein; Paul L Molina; Joanne Quan; Judy A Bean; Robert W Wilmott
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

View more
  14 in total

1.  Influence of radiation dose and reconstruction algorithm in MDCT assessment of airway wall thickness: A phantom study.

Authors:  Daniel Gomez-Cardona; Scott K Nagle; Ke Li; Terry E Robinson; Guang-Hong Chen
Journal:  Med Phys       Date:  2015-10       Impact factor: 4.071

2.  A semiquantitative MRI-Score can predict loss of lung function in patients with cystic fibrosis: Preliminary results.

Authors:  Juergen F Schaefer; Andreas Hector; Katharina Schmidt; Matthias Teufel; Sabrina Fleischer; Ute Graepler-Mainka; Joachim Riethmueller; Sergios Gatidis; Susanne Schaefer; Konstantin Nikolaou; Dominik Hartl; Ilias Tsiflikas
Journal:  Eur Radiol       Date:  2017-06-29       Impact factor: 5.315

3.  Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

Review 4.  Timing of dornase alfa inhalation for cystic fibrosis.

Authors:  Ruth Dentice; Mark Elkins
Journal:  Cochrane Database Syst Rev       Date:  2016-07-26

5.  Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Katelyn Parker-McGill; Philip Farrell; Alan S Brody
Journal:  Pediatr Pulmonol       Date:  2018-08-29

6.  Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis.

Authors:  Matthew M Willmering; David J Roach; Elizabeth L Kramer; Laura L Walkup; Zackary I Cleveland; Jason C Woods
Journal:  J Cyst Fibros       Date:  2020-12-04       Impact factor: 5.482

7.  Dornase alfa for cystic fibrosis.

Authors:  Connie Yang; Mark Montgomery
Journal:  Cochrane Database Syst Rev       Date:  2021-03-18

8.  Timing of dornase alfa inhalation for cystic fibrosis.

Authors:  Ruth Dentice; Mark Elkins
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09

9.  Timing of dornase alfa inhalation for cystic fibrosis.

Authors:  Ruth Dentice; Mark Elkins
Journal:  Cochrane Database Syst Rev       Date:  2018-11-12

Review 10.  Dornase alfa for cystic fibrosis.

Authors:  Connie Yang; Mark Montgomery
Journal:  Cochrane Database Syst Rev       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.